BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novartis (NVS) Warns Jobs May Go Overseas


11/26/2012 8:23:15 AM

The Government must tackle the red-tape and research hold-ups hampering Britain’s pharmaceutical industry or risk seeing jobs and investment disappear overseas, one of the industry’s leading companies has warned. Swiss pharmaceuticals giant Novartis has arranged a crisis meeting of scientists, NHS trustees and Government officials starting today in London in a bid to streamline Britain’s “haphazard” approach to medical research and development (R&D). Science Minister David Willetts is due to attend the meeting, thought to be the first to unite representatives of Big Pharma and the medical profession on a large scale. In a stark warning to the Government ahead of the Autumn Statement, Jon Symonds, global finance director of Novartis, which allocates $10bn in R&D a year, will say that Britain is losing competitiveness to emerging markets and Asia. Ahead of the meeting, Mr Symonds told The Daily Telegraph, that while the UK has made “great strides” in supporting life sciences, the Government must be more radical and move far faster. He said bringing a drug to an NHS trust, securing clinical trials and getting approval, is inefficient and takes too long. “It should be a seamless process but instead it takes an enormous amount of time and energy, during which we lose money,” he said. It can cost $1bn to bring a new drug to market, he said, but pharmaceutical companies usually just get a few months before a patent runs out so delays in getting trials and approval can be make or break. Yet often NHS trusts are slow to take-up new drugs or help organise trials.

Read at Telegraph
Read at Pharmalot
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES